ReviewBMC public health2015
The humanistic, economic and societal burden of herpes zoster in Europe: a critical review.
Review in BMC public health, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Global herpes zoster burden in adults with asthma: a systematic review and meta-analysis.The European respiratory journal · 2024Pooled it
- Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2021Trial
- The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial.The journals of gerontology. Series A, Biological sciences and medical sciences · 2019Trial
- Trial
- Quantitative study of the knowledge, attitudes, and practices (KAP) towards herpes zoster (HZ) and HZ vaccination: Survey findings from a multi-country study in Asia (ZOASIS).Human vaccines & immunotherapeutics · 2026Article
- BC02-adjuvanted varicella-zoster virus glycoprotein E subunit vaccine overcomes immunosenescence to induce robust neutralizing antibodies and multifunctional T-cell immunity in seropositive aged murine models.Human vaccines & immunotherapeutics · 2026Article
- Exploring spillovers of vaccines: A practical application of the Expanded Impact Inventory.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Application of Virtual Reality in Pain Management of Patients with Postherpetic Neuralgia: A Randomized Controlled Trial.Pain and therapy · 2026Article
- Efficacy and safety of stellate ganglion block for postherpetic neuralgia: a systematic review and meta-analysis protocol.BMJ open · 2026Article
- Unlocking herpes zoster vaccination value in Finland: return on investment and actuarial model.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Cost Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Older Adults in Portugal.PharmacoEconomics - open · 2026Article
- Estimation of Costs Related to the Management of Herpes Zoster and its Complications in Vietnam: A Medical Chart Review.Infectious diseases and therapy · 2026Article
- Elevated Risk of Herpes Zoster in Vitiligo Patients: A Nationwide Population-Based Cohort Study of Taiwan.The Journal of dermatology · 2026Article
- Prediction of Postherpetic Neuralgia in Patients with Acute and Subacute Herpetic Neuralgia Using Structural Magnetic Resonance Imaging: A Retrospective Study.Pain and therapy · 2026Article
- Spatial-temporal dynamics of HZ prevalence among high-risk groups: a global multiregional cohort analysis since 1990.Virology journal · 2025Article
- Predictive model of public health impact of herpes zoster vaccination and related costs for adults aged ≥50 years in Republic of Korea.Human vaccines & immunotherapeutics · 2025Article
- Cost burden and temporal trends of herpes zoster in China: Evidence from Beijing's health records.Preventive medicine reports · 2025Article
- The Economic Burden of Herpes Zoster in Individuals Aged 50 Years or Older and Those With Underlying Conditions in Italy.Open forum infectious diseases · 2025Article
- Knowledge, attitude, and practice toward herpes zoster (HZ) and HZ vaccination: Concept elicitation findings from a multi-country study in the Asia Pacific.Human vaccines & immunotherapeutics · 2024Article
- Logistic and organizational barriers to herpes zoster vaccination in europe: A systematic review.Vaccine: X · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHerpes zoster (HZ) or "shingles" is common in persons aged 50 years or over. HZ is characterised by a painful dermatological rash which typically resolves in approximately one month. Persistent pain for months or years after rash onset, however, is a common complication of HZ; referred to as post-herpetic neuralgia (PHN). Both HZ and PHN have a significant impact on patients' lives, with considerable implications for healthcare systems and wider society. The aim of the present review is to provide comprehensive documentation and critical appraisal of published data concerning the humanistic, economic and societal burden of HZ in Europe.
methodsSystematic literature searches were conducted in Medline, EMBASE, PsycINFO, EconLit, HEED and CRD databases. Searches were conducted in July 2014 and restricted to articles published in the past 20 years. Articles were selected for full review by two independent researchers in accordance with predefined eligibility criteria.
resultsFrom a review of 1619 abstracts, 53 eligible articles, were identified which reported data concerning healthcare resource use (n = 38), direct costs (n = 20), indirect costs (n = 16), total costs (n = 10) and impact on health-related quality of life (HRQoL) (n = 21). Findings highlight that PHN is associated with greater impairments in HRQoL and higher costs of management than HZ. For both HZ and PHN, pain severity is a significant predictor of impact on individuals, healthcare systems and society. While the incidence of HZ and PHN increase with age, age does not appear to be a key driver of overall costs for HZ and PHN. Specifically, while direct costs (e.g. GP, specialists, medications, hospitalisations) tend to be higher for older patients, indirect costs (e.g. work time missed) are higher for younger patients.
conclusionsAvailable evidence highlights that HZ and PHN result in significant humanistic and economic burden for patients, healthcare systems and wider societies. A tendency to focus upon healthcare resource use and the direct costs of management at the expense of other impacts (e.g. informal caregivers and formal social care) may result in an underestimation of the true burden of HZ and PHN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.